Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Early clinical trials conducted primarily in Japan have shown that TAS-102, an oral agent that combines trifluridine and tipiracil hydrochloride, was effective in the treatment of refractory colorectal cancer. We conducted a phase 3 trial to further assess the efficacy and safety of TAS-102 in a global population of such patients. METHODS: In this double-blind study, we randomly assigned 800 patients, in a 2:1 ratio, to receive TAS-102 or placebo. The primary end point was overall survival. RESULTS: The median overall survival improved from 5.3 months with placebo to 7.1 months with TAS-102, and the hazard ratio for death in the TAS-102 group versus the placebo group was 0.68 (95% confidence interval [CI], 0.58 to 0.81; P<0.001). The most frequently observed clinically significant adverse events associated with TAS-102 were neutropenia, which occurred in 38% of those treated, and leukopenia, which occurred in 21%; 4% of the patients who received TAS-102 had febrile neutropenia, and one death related to TAS-102 was reported. The median time to worsening performance status (a change in Eastern Cooperative Oncology Group performance status [on a scale of 0 to 5, with 0 indicating no symptoms and higher numbers indicating increasing degrees of disability] from 0 or 1 to 2 or more) was 5.7 months with TAS-102 versus 4.0 months with placebo (hazard ratio, 0.66; 95% CI, 0.56 to 0.78; P<0.001). CONCLUSIONS: In patients with refractory colorectal cancer, TAS-102, as compared with placebo, was associated with a significant improvement in overall survival. (Funded by Taiho Oncology-Taiho Pharmaceutical; RECOURSE ClinicalTrials.gov number, NCT01607957.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Third-line treatment options are limited to regorafenib and trifluridine–tipiracil, which have extended median overall survival by less than 2 months over placebo and have been associated with a low response rate (<2%) and median progression-free survival of approximately 2 months, outcomes that highlight the need for new approaches.15,16”
From Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C (2023) · cites this paper as [16]
In the citing paper
“Findings in the monotherapy cohort also compared favorably with the results of a trial of regorafenib (another third-line treatment) involving 505 patients, who had a response of 1.0%, progression-free survival of 1.9 months, and overall survival of 6.4 months.15,16”
From Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C (2023) · cites this paper as [16]
In the citing paper
“As described in the drug package insert, the efficacy and safety have not been established in the primary or secondary treatments [99, 100].”
From Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer (2018) · cites this paper as [100]
In the citing paper
“Nevertheless, single-agent garsorasib and the combination of garsorasib and cetuximab achieved considerable ORRs of 19.2% and 45.2%, and a trend toward prolonged PFS and OS, as compared with the standard-of-care includes regorafenib and trifluridine/tipiracil, which demonstrated an ORR of 1.0% and 1.6%, respectively.30,31”
In the citing paper
“The phase 3 RECOURCE trial evaluated TAS-102 vs. placebo in metastatic CRC patients refractory to standard chemotherapies [44]. TAS-102 significantly improved mOS to 7.1 months compared to 5.3 months with placebo (HR for death: 0.68, 95% CI 0.58–0.81).”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [44]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Van Cutsem, E., Cervantes, A., Nordlinger, B., & Arnold, D. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu260 · Cited by 1,167
Systemic Therapy for Colorectal Cancer
Meyerhardt, J. A., & Mayer, R. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmra040958 · Cited by 1,043
Self-citationSystemic Therapy for Colorectal Cancer
Varghese, A. M. (2019) · DeckerMed CGSO Case-Based Reviews · doi:10.2310/cgso.16189 · Cited by 883
Use of Statins and the Risk of Death in Patients With Prostate Cancer
Yu, O., Eberg, M., Benayoun, S., Aprikian, A., Batist, G., Suissa, S., & Azoulay, L. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.4757 · Cited by 659
Yoshino, T., Mizunuma, N., Yamazaki, K., Nishina, T., Komatsu, Y., Baba, H., Tsuji, A., Yamaguchi, K., Muro, K., Sugimoto, N., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70345-5 · Cited by 326
Self-citationFukushima, M., Suzuki, N., Emura, T., Yano, S., Kazuno, H., Tada, Y., Yamada, Y., & Asao, T. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00253-7 · Cited by 239
Tanaka, N., Sakamoto, K., Okabe, H., Fujioka, A., Yamamura, K., Nakagawa, F., Nagase, H., Yokogawa, T., Oguchi, K., Ishida, K., et al. (2014) · Oncology Reports · doi:10.3892/or.2014.3487 · Cited by 149
Emura, T., Suzuki, N., Yamaguchi, M., Ohshimo, H., & Fukushima, M. (2004) · International Journal of Oncology · doi:10.3892/ijo.25.3.571 · Cited by 120
A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells
Emura, T., Murakami, Y., Nakagawa, F., Fukushima, M., & Kitazato, K. (2004) · International Journal of Molecular Medicine · doi:10.3892/ijmm.13.4.545 · Cited by 104
Research works printed but not linked: 6
- Sobrero A, 2000, Semin Oncol, 27, 72
- Emura T, 2004, Int J Mol Med, 13, 545
- Emura T, 2004, Int J Oncol, 25, 571
- Heidelberger C, 1964, Cancer Res, 24, 1979
- Heidelberger C, 1965, Cancer Res, 25, 377
- Dexter DL, 1972, Cancer Res, 32, 247
Cited by
Items 701–800 of 1,000
Combination Therapy, Including Bevacizumab, for Advanced Colorectal Cancer
Yeku, O., & Longo, D. L. (2023) · New England Journal of Medicine · doi:10.1056/nejme2300385 · Cited by 8
Advances in Therapies Targeting Inhibitory Checkpoint Receptors: TIGIT, LAG-3, and Beyond
Healy, J. A., Han, J., Bauché, D., Keenan, T. E., Casasnovas-Nieves, J., & Dobrenkov, K. (2023) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-061521-093717 · Cited by 8
Thibaudin, M., Roussot, N., Burlot, C., Schmitt, A., Vincent, J., Tharin, Z., Bengrine-Lefèvre, L., Bellio, H., Bertaut, A., Hampe, L., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02116-4 · Cited by 7
Cherri, S., Libertini, M., Noventa, S., Oneda, E., Meriggi, F. A., & Zaniboni, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062522 · Cited by 9
Self-citationCann, C., LaPelusa, M. B., Cimino, S. K., Cancelliere, V., Dow-Hillgartner, E. N., Zhao, Z., Deming, D. A., & Eng, C. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf099 · Cited by 7
Yang, F., Mao, Y. Q., Huang, H., Luo, W., Liu, L., & Chen, W. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1579293 · Cited by 9
9 weeks that matter for patients with gastric cancer
Nienhüser, H., & Schmidt, T. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30752-6 · Cited by 7
Recomendaciones para diagnóstico y tratamiento del cáncer de colon y recto en México
Torrecillas-Torres, L., Cervantes-Sánchez, M. G., Adame-González, I., Bornstein-Quevedo, L., Calderillo-Ruiz, G., Cárdenas-Cárdenas, E., Sánchez, I. E. C., Farias-Alarcón, M. A., Orozco, A. F., Hernández-Hernández, C., et al. (2019) · Gaceta Mexicana de Oncología · doi:10.24875/j.gamo.m19000187 · Cited by 17
Oda, Y., & Narukawa, M. (2022) · BMC Cancer · doi:10.1186/s12885-022-09383-w · Cited by 7
Cecchini, M., Zhang, J. Y., Wei, W., Sklar, J., Lacy, J., Zhong, M., Kong, Y., Zhao, H., DiPalermo, J., Devine, L., et al. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0045 · Cited by 7
Watanabe, D., Fujii, H., Ohata, K., Iihara, H., Makiyama, A., Kobayashi, R., Hirose, C., Sadaka, S., Matsuoka, S., Tajima, J. Y., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-11618-3 · Cited by 8
van Nassau, S. C. M. W., Bol, G. M., van der Baan, F. H., Roodhart, J. M. L., Vink, G. R., Punt, C. J. A., May, A. M., Koopman, M., & Derksen, J. W. G. (2024) · Current Treatment Options in Oncology · doi:10.1007/s11864-024-01186-4 · Cited by 8
Duan, J., Zhu, L., Shi, Y., Wang, W., Wang, T., Ning, T., Zhang, L., Bai, M., Li, H., Liu, R., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-12072-5 · Cited by 9
Ottaiano, A., Santorsola, M., Ianniello, M., Ceccarelli, A., Casillo, M., Sabbatino, F., Petrillo, N., Cascella, M., Caraglia, F., Picone, C., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05184-w · Cited by 7
Hernando‐Calvo, A., Han, M., Ayodele, O., Wang, B. X., Bruce, J. P., Aghababazadeh, F. A., Vila-Casadesús, M., Sanz‐García, E., Yang, S. Y. C., Berman, H. K., et al. (2024) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2024.05.002 · Cited by 15
Taïeb, J., Fakih, M., Tabernero, J. M., Ciardiello, F., Cutsem, E. V., Soler, G., Calleja, E. M., Barboux, V., Roby, L., Amellal, N., et al. (2024) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2024.12.002 · Cited by 11
Self-citationStintzing, S., Tabernero, J. M., Satoh, T., Dasari, A. N., Lonardi, S., Eng, C., Garcia-Carbonero, R., Élez, E., Yoshino, T., Sobrero, A. F., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.104297 · Cited by 7
Self-citationMizushima, T., Fukunaga, M., Sueda, T., Ikeda, M., Kato, T., Kim, H. M., Kudo, T., Murata, K., Nishimura, J., Hata, T., et al. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3336-3 · Cited by 9
Kim, S.-Y., Jung, J. H., Lee, H. J., Soh, H., Lee, S. J., Oh, S. J., Chae, S. Y., Lee, J. H., Lee, S. J., Hong, Y. S., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1406 · Cited by 7
Winer, A., Denlinger, C. S., Vijayvergia, N., Cohen, S. J., Astsaturov, I. A., Dotan, E., Gallant, J., Wang, W., Kunkel, M., Lim, B., et al. (2020) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2020.08.003 · Cited by 7
Nakajima, H., Fukuoka, S., Masuishi, T., Takashima, A., Kumekawa, Y., Kajiwara, T., Yamazaki, K., Negoro, Y., Komoda, M., Makiyama, A., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.688709 · Cited by 8
Self-citationO'Leary, M. P., Wang, C., Sandhu, J. S., Malhotra, G. K., Thornblade, L. W., Lau, C. P.-Y., Melstrom, L. G., Fong, Y., Singh, G. P., & Fakih, M. (2021) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2021.10.032 · Cited by 7
TAS-102 Monotherapy and Combination Therapy with Bevacizumab for Metastatic Colorectal Cancer
Liu, C.-J., Hu, T., Shao, P., Chu, W.-Y., Cao, Y., & Zhang, F. (2021) · Gastroenterology Research and Practice · doi:10.1155/2021/4014601 · Cited by 9
Mauri, G., Rossi, D., Frassoni, S., Bonomo, G., Camisassi, N., Vigna, P. D., Bagnardi, V., Maiettini, D., Varano, G. M., Zampino, M. G., et al. (2022) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-021-03039-1 · Cited by 7
D'Onofrio, R., Caputo, F., Prampolini, F., Spallanzani, A., Gelsomino, F., Bettelli, S. R., Manfredini, S., Bonetti, L. R., Carotenuto, P., Bocconi, A., et al. (2022) · Tumori Journal · doi:10.1177/03008916221122554 · Cited by 7
Poad, H., Khan, S., Wheaton, L., Thomas, A., Sweeting, M. J., & Bujkiewicz, S. (2022) · Cancers · doi:10.3390/cancers14215391 · Cited by 9
Yoshida, N., Kuriu, Y., Ikeda, J., Kudou, M., Kirishima, T., Okayama, T., Miyagawa, K., Takagi, T., Nakanishi, M., Doi, T., et al. (2023) · International Journal of Clinical Oncology · doi:10.1007/s10147-023-02389-9 · Cited by 7
Real-World Outcomes in Patients with Metastatic Colorectal Cancer in Spain: The RWD-ACROSS Study
Pericay, C., Montés, A. F., Alonso-Orduña, V., Macías, I., Asensio, E., Salas, N. R., Torres, E., Lavín, D. C., Rodríguez-Alonso, R. M., Falcó, E., et al. (2023) · Cancers · doi:10.3390/cancers15184603 · Cited by 8
Moretto, R., Germani, M. M., Ros, J., Daniel, F., Ghelardi, F., Vetere, G., Giordano, M., Toledo, R. A., Bergamo, F., Randon, G., et al. (2023) · JCO Precision Oncology · doi:10.1200/po.23.00255 · Cited by 7
Zou, J., Wang, Y., Xu, J., Li, J., Wang, T., Zhang, Y., & Bai, Y. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm13010057 · Cited by 7
Cohen, R., Raeisi, M., Chibaudel, B., Yoshino, T., Shi, Q., Zalcberg, J. R., Adams, R., Cremolini, C., Grothey, A. A., Mayer, R. J., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.113537 · Cited by 7
Self-citationA phase I/II study of nintedanib and capecitabine for refractory metastatic colorectal cancer
Boland, P. M., Ebos, J. M. L., Attwood, K. M., Mastri, M., Fountzilas, C. K., Iyer, R. V., Banker, C., Goey, A. K. L., Bies, R. R., Ma, W. W., et al. (2024) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkae017 · Cited by 9
Translational research and application of basic biology to clinical trial development in GI cancers
Smyth, E. C., Khan, K. H., & Valeri, N. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.05.05 · Cited by 7
Survival outcome and prognostic model of patients with colorectal cancer on phase 1 trials
Kam, A. E., Pendurti, G., Shah, U. H., Ghalib, M. H., Chaudhary, I., Chuy, J. W., Rajdev, L. N., Kaubisch, A., Aparo, S., Mantzaris, I., et al. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0675-9 · Cited by 7
Up-and-Coming Experimental Drug Options for Metastatic Colorectal Cancer
Cimino, S. K., & Eng, C. (2020) · Journal of Experimental Pharmacology · doi:10.2147/jep.s259287 · Cited by 9
Cutsem, E. V., Höchster, H. S., Shitara, K., Mayer, R. J., Ohtsu, A., Falcone, A., Yoshino, T., Doi, T., Ilson, D. H., Arkenau, H., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100633 · Cited by 7
Self-citationCercek, A., Gendel, V. M., Jabbour, S. K., Moore, D. F., Chen, C., Nosher, J. L., Capanu, M., Chou, J. F., Boucher, T. M., Kemeny, N. E., et al. (2017) · Current Treatment Options in Oncology · doi:10.1007/s11864-017-0481-1 · Cited by 8
Ramaekers, B. L. T., Wolff, R. F., van Giessen, A., Pouwels, X., Fayter, D., Lang, S., Armstrong, N., Worthy, G., Duffy, S., Kleijnen, J., et al. (2017) · PharmacoEconomics · doi:10.1007/s40273-017-0591-4 · Cited by 7
Yoshida, Y., Yamada, T., Matsuoka, H., Sonoda, H., Fukazawa, A., Yoshida, H., Ishida, H., Hirata, K., Hasegawa, S., Sakamoto, K., et al. (2019) · Journal of the Anus Rectum and Colon · doi:10.23922/jarc.2018-043 · Cited by 7
Fujimoto, Y., Nakanishi, R., Nukatsuka, M., Matsuoka, K., Ando, K., Wakasa, T., Kitao, H., Oki, E., Maehara, Y., & Mori, M. (2020) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-020-04072-6 · Cited by 7
Wheelden, M., & Yee, N. S. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s216598 · Cited by 7
Hirano, S., Gohda, Y., Miyazaki, H., Hayama, N., Shimizu, S., Igari, T., & Yano, H. (2021) · Chinese Clinical Oncology · doi:10.21037/cco-21-2 · Cited by 7
Chen, Y., Zhou, Y., Cheng, K., Li, Z., Luo, D., Qiu, M., Li, Q., Wang, X., Shen, Y., Cao, D., et al. (2021) · The Oncologist · doi:10.1002/onco.13778 · Cited by 6
Huang, F., Yang, H., Bao, W., Bin, Y., Zhou, S., Wang, M., & Lv, X. (2023) · Clinical and Translational Oncology · doi:10.1007/s12094-023-03268-5 · Cited by 6
Dou, X., Zhao, L., Ma, Z., Wei, L., Jiang, X. M., Ding, Y., Sun, S., Sun, Y., Li, M., Feng, R. E., et al. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103312 · Cited by 7
Systemic therapy strategies for elderly patients with gastric cancer
Narita, Y., & Muro, K. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251363057 · Cited by 6
Qi, C., Liu, C., Gong, J., Wang, X., Wang, Z., Xu, T., Liu, D., Zhang, P., Li, J., Zhang, M., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-01090 · Cited by 9
Li, N., Deng, W., Zhang, G., Du, Y., Guo, Y. W., Ma, Y., Chen, W., Bie, L., Zhang, C., Song, T., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.728854 · Cited by 6
Radioembolization in the Setting of Systemic Therapies
Mabud, T. S., & Hickey, R. (2021) · Seminars in Interventional Radiology · doi:10.1055/s-0041-1735572 · Cited by 6
AZD6738 promotes the tumor suppressive effects of trifluridine in colorectal cancer cells
Harata, S., Suzuki, T., Takahashi, H., Hirokawa, T., Kato, A., Watanabe, K., Yanagita, T., Ushigome, H., Shiga, K., Ogawa, R., et al. (2023) · Oncology Reports · doi:10.3892/or.2023.8489 · Cited by 9
Kehmann, L., Berres, M., Gonzalez-Carmona, M. A., Modest, D. P., Mohr, R. U., Wree, A., Venerito, M., Strassburg, C., Keitel, V., Trautwein, C., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-10972-6 · Cited by 6
Avelumab in Patients With Metastatic Colorectal Cancer
Redman, J. M., Coyne, G. O., Reed, C. T., Madan, R. A., Strauss, J., Steinberg, S. J., Marté, J. L., Cordes, L. M., Heery, C. R., & Gulley, J. L. (2023) · The Oncologist · doi:10.1093/oncolo/oyad162 · Cited by 6
Shiroyama, M., Fukuoka, S., Masuishi, T., Takashima, A., Kumekawa, Y., Kajiwara, T., Yamazaki, K., Shimada, Y., Esaki, T., Makiyama, A., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-45244-7 · Cited by 6
Self-citationDoleschal, B., Taghizadeh, H., Lentner, T., Riedl, J. M., Granitzer, J., Morariu, D. Ș., Decker, J., Aichberger, K. J., Webersinke, G., Kirchweger, P., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.102064 · Cited by 7
Taşçı, E. Ş., Oyan, B., Sönmez, Ö., Mutlu, A. U., Atçı, M. M., Sakin, A., Öner, İ., Çınkır, H. Y., Eryılmaz, M. K., Çağlayan, D., et al. (2024) · BMC Cancer · doi:10.1186/s12885-023-11783-5 · Cited by 9
de Azeredo-da-Silva, A. L. F., de Jesus, V. H. F., Agirrezabal, I., Brennan, V. K., Carion, P. L., Amoury, N., Vetromilla, B. M., Zanotto, B. S., Shergill, S., & Ziegelmann, P. K. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02800-5 · Cited by 7
Basso, M., Signorelli, C., Calegari, M. A., Lucchetti, J., Zurlo, I. V., Dell’Aquila, E., Arrivi, G., Zoratto, F., Santamaria, F., Saltarelli, R., et al. (2024) · Targeted Oncology · doi:10.1007/s11523-024-01050-3 · Cited by 6
An, T.-Q., Qiu, H., Zhou, Q.-B., Zong, H., Hu, S., Lian, Y.-G., & Zhao, R. (2024) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v16.i6.2449 · Cited by 8
Paly, V. F., Dasari, A. N., Hubbard, J. M., Bekaii‐Saab, T., Padukkavidana, T., & Hernandez, L. G. (2024) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2024-0084 · Cited by 6
Beyaztaş, H., Bozalı, K., Koç, S., Özdemir, M., Yalçın, B., & Güler, E. M. (2024) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2024.111287 · Cited by 7
Malier, M., Laverrière, M., Henry, M., Yakoubi, M., Bellaud, P., Arellano, C., Sébillot, A., Thomas, F., Josserand, V., Girard, É., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217307 · Cited by 6
Fong, W. P., Li, Z., Ren, C., Guan, W., Zuo, M., Zhang, T., Li, B., Zheng, Y., Wu, X., Ding, P., et al. (2024) · HPB · doi:10.1016/j.hpb.2024.11.008 · Cited by 6
Signorelli, C., Calegari, M. A., Anghelone, A., Passardi, A., Frassineti, G. L., Bittoni, A., Lucchetti, J., Angotti, L., Giacomo, E. D., Zurlo, I. V., et al. (2024) · Current Oncology · doi:10.3390/curroncol31120574 · Cited by 6
Mulet-Margalef, N., Matos, I. G., Noguerido, A., Martini, G., Elez, M. E., Argilés, G., & Tabernero, J. M. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1453497 · Cited by 6
Self-citationMetastatic Bulk Independently Predicts Outcomes for EGFR Precision Targeting in Colorectal Cancer
Kratz, J. D., Uboha, N. V., Lubner, S. J., Mulkerin, D. L., Clipson, L. J., Yi, Y., Yu, M., Matkowskyj, K. A., LoConte, N. K., & Deming, D. A. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.7074 · Cited by 6
Tsunekuni, K., Kawakami, H., Matsuoka, K., Nagase, H., Mitani, S., & Nakagawa, K. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9124050 · Cited by 6
Selection of Oral Therapeutics in China for the Treatment of Colorectal Cancer
Li, J., Cai, Y., & Deng, Y. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00852-1 · Cited by 6
Archwamety, A., Teeyapun, N., Siripoon, T., Poungvarin, N., Tanasanvimon, S., Sirachainan, E., Akewanlop, C., & Korphaisarn, K. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.813009 · Cited by 8
Hamers, P. A. H., Wensink, G. E., van Smeden, M., Vink, G. R., Smabers, L. P., Lunenberg, R. A., Laclé, M. M., Koopman, M., May, A. M., & Roodhart, J. M. L. (2022) · Cancers · doi:10.3390/cancers14205094 · Cited by 6
da Silva, S. P. C., Jesus, M., Roque, F., Herdeiro, M. T., Sousa, R. C. E., Duarte, A. P., & Morgado, M. (2023) · Current Oncology · doi:10.3390/curroncol30040315 · Cited by 6
Tas-102 for Refractory Metastatic Colorectal Cancer: A Multicenter Retrospective Cohort Study
Conti, M., Bolzacchini, E., Luchena, G., Bertù, L., Tagliabue, P. F., Aglione, S., Ardizzoia, A., Arnoffi, J., Guida, F. M., Bertolini, A., et al. (2023) · Cancers · doi:10.3390/cancers15133465 · Cited by 6
Difference in Neutropenia due to Administration Schedule of TAS-102
Yoshida, Y., Aisu, N., Mogi, A., Komono, A., Sakamoto, R., Kojima, D., Mera, T., & Hasegawa, S. (2017) · Case Reports in Oncology · doi:10.1159/000460242 · Cited by 6
Sunakawa, Y., Izawa, N., Mizukami, T., Horie, Y., Hirakawa, M., Arai, H., Ogura, T., Tsuda, T., & Nakajima, T. E. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s106101 · Cited by 6
Thymidine Phosphorylase: The Unforeseen Driver in Colorectal Cancer Treatment?
Tampellini, M., Bironzo, P., Maïo, M. D., & Scagliotti, G. V. (2018) · Future Oncology · doi:10.2217/fon-2017-0627 · Cited by 7
Evaluating the recent developments in palliative chemotherapy for metastatic colorectal cancer
Baek, S. K., Lee, K. T., Bae, S. B., & Lee, S. (2019) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2019.071 · Cited by 6
Siebenhüner, A. R., Dosso, S. D., Meisel, A., Wagner, D., & Borner, M. (2020) · Oncology Research and Treatment · doi:10.1159/000506080 · Cited by 6
Zhang, P., Xie, D., & Li, Q. (2020) · Tumori Journal · doi:10.1177/0300891620916789 · Cited by 7
An appraisal of emerging second line therapies for metastatic colorectal cancer
Smolenschi, C., Perret, A., Dall'Armellina, F., Boige, V., Malka, D., Hollebecque, A., & Ducreux, M. P. (2020) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2021.1840975 · Cited by 6
Kato, T., Kagawa, Y., Kuboki, Y., Gamoh, M., Komatsu, Y., Yasui, H., Satake, H., Oki, E., Tanioka, H., Kotaka, M., et al. (2021) · International Journal of Clinical Oncology · doi:10.1007/s10147-021-01902-2 · Cited by 7
Self-citationMoehler, M. H., Michel, M. S., Stein, A., Trojan, J., Marquardt, J. U., Tintelnot, J., Waidmann, O., Weinmann, A., Woerns, M.-A., Schroeder, H., et al. (2021) · Future Oncology · doi:10.2217/fon-2021-0278 · Cited by 6
Bjørnelv, G. M. W., Zolic-Karlsson, Z., Dueland, S., Line, P., & Aas, E. (2022) · British journal of surgery · doi:10.1093/bjs/znac022 · Cited by 6
Chuang, J., Gong, J., Li, S. M., Wang, C., & Fakih, M. (2022) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2022.05.004 · Cited by 6
Kobunai, T., Matsuoka, K., & Takechi, T. (2019) · Anticancer Research · doi:10.21873/anticanres.13502 · Cited by 6
Safety Report of TAS-102 in a Patient With Reduced DPD Activity
Bolzacchini, E., Luchena, G., & Giordano, M. (2019) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2019.07.008 · Cited by 6
Lin, Y., Liu, K., & Lin, B. (2020) · Medicine · doi:10.1097/md.0000000000022780 · Cited by 6
Chida, K., Kotani, D., Moriwaki, T., Fukuoka, S., Masuishi, T., Takashima, A., Kumekawa, Y., Kajiwara, T., Yamazaki, K., Komoda, M., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.576036 · Cited by 6
Self-citationAngiogenesis inhibitors for metastatic colorectal cancer
Pfeiffer, P., Liposits, G. I., & Tarpgaard, L. S. (2023) · Translational Cancer Research · doi:10.21037/tcr-23-1568 · Cited by 7
Köhler, B. C., Haag, G. M., Cornet, L. L., Hoffmeister‐Wittmann, P., Schmidt, M., Manjunath, A., Vaquero‐Siguero, N., Jenzer, M., Gimmel, M., Stahler, A., et al. (2025) · ESMO Gastrointestinal Oncology · doi:10.1016/j.esmogo.2024.100118 · Cited by 8
Ding, Y., Feng, Y. D., Ye, Y., Shen, J., Guo, C., He, X., Zhu, L., & Wang, L. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1503517 · Cited by 8
Ottaiano, A., Santorsola, M., Perri, F., Granata, V., Cascella, M., Sabbatino, F., & Nasti, G. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12020596 · Cited by 6
Sequencing considerations in the third-line treatment of metastatic colorectal cancer
Barzi, A., & Bekaii‐Saab, T. (2024) · The American Journal of Managed Care · doi:10.37765/ajmc.2024.89546 · Cited by 7
Hu, Y., Du, Y., Qiu, Z., Zhu, C., Wang, J., Liang, T., Liu, T., & Da, M. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1399998 · Cited by 5
Chen, X., Wang, L., Lei, X., Lei, X., Li, Z., Diao, Y., Zhang, S., Li, C., Wang, C., Guo, Q., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1429095 · Cited by 6
Fakih, M., Prager, G. W., Tabernero, J. M., Amellal, N., Calleja, E., & Taïeb, J. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103931 · Cited by 6
Self-citationLiu, C., Chen, J., & Liu, Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-86575-x · Cited by 5
RetractedCurrent status and advances in the treatment of colorectal cancer with liver metastases
Liu, W., Jiang, C., & Li, J. (2025) · World Journal of Clinical Oncology · doi:10.5306/wjco.v16.i7.107438 · Cited by 8
Kotani, D., Yoshino, T., Masuishi, T., Sunakawa, Y., Takashima, A., Yamazaki, K., Kawakami, H., Nishina, T., Komatsu, Y., Esaki, T., et al. (2025) · International Journal of Clinical Oncology · doi:10.1007/s10147-025-02852-9 · Cited by 5
Self-citationSugiura, K., Seo, Y., Takahashi, T., Tokura, H., Ito, Y., Tanaka, M., Kishida, N., Nishi, Y., Onishi, Y., & Aoki, H. (2021) · BMC Gastroenterology · doi:10.1186/s12876-021-01771-z · Cited by 5
Correa, E., Lindsay, T., & Dotan, E. (2021) · Drugs & Aging · doi:10.1007/s40266-021-00869-z · Cited by 6
Tong, D. K. H., Wang, L., Mendis, J. R., & Essapen, S. (2021) · Current Oncology · doi:10.3390/curroncol28030208 · Cited by 6
Metadata
- Authors
- Mayer, R. J., Van Cutsem, E., Falcone, A., Yoshino, T., Garcia-Carbonero, R., Mizunuma, N., Yamazaki, K., Shimada, Y., Tabernero, J., Komatsu, Y., Sobrero, A., Boucher, E., Peeters, M., Tran, B., Lenz, H.-J., Zaniboni, A., Hochster, H., Cleary, J. M., Prenen, H., Benedetti, F., Mizuguchi, H., Makris, L., Ito, M., & Ohtsu, A.
- Affiliations
- University of Pisa (IT)
- National Cancer Center Hospital East (JP)
- Centre Eugène Marquis (FR)
- The Royal Melbourne Hospital (AU)
- USC Norris Comprehensive Cancer Center (US)
- Yale Cancer Center (US)
- Taiho Oncology (United States) (US)
- Ospedale Policlinico San Martino (IT)
- Antwerp University Hospital (BE)
- University of Southern California (US)
- Fondazione Poliambulanza Istituto Ospedaliero (IT)
- Dana-Farber Cancer Institute (US)
- KU Leuven (BE)
- Taiho Pharmaceutical (Japan) (JP)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-05-14
- Volume
- 372
- Issue
- 20
- Pages
- 1909-1919
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W242040007
- Semantic Scholar
- 3d08304a7bda1c2d5aa4ab9b3aa96bc534c22f58
- Cited by
- 1,431
- References
- 20
- Citations by year
- 2026: 97 · 2025: 136 · 2024: 165 · 2023: 145 · 2022: 150 · 2021: 138 · 2020: 150 · 2019: 112 · 2018: 115 · 2017: 116 · 2016: 79 · 2015: 27
- FWCI
- 49.50
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Keywords
- trifluridine/tipiracil, trifluridine, tipiracil, metastatic colorectal cancer, refractory colorectal cancer, oral chemotherapy, overall survival, neutropenia, leukopenia, febrile neutropenia, performance status, drug safety
- MeSH terms
- Adenocarcinoma, Adult, Aged, Aged, 80 and over, Double-Blind Method, Drug Combinations, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Pyrrolidines, Thymine, Trifluridine, Uracil, Colorectal Neoplasms, Proportional Hazards Models, Survival Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.